However in September, Barclays suffered negative press coverage because of the Protium transaction and the share price ascent stalled. Protium mitigates Barclays' mark-to-market and monoline exposure on some $12 billion of toxic assets. The transaction reminded people that Barclays still has problem assets on its balance sheet. I have always maintained that press coverage follows the business. So I do not blame Barclays Capital's media team for this negative coverage.